ETNB - Inventiva Phase 2 study for MASH drug meets primary endpoint
2024-03-18 17:45:43 ET
More on Inventiva
- Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause
- Inventiva resumes Phase 3 study for NASH drug, stock up 6%
- Inventiva drops after adverse event in Phase 3 trial for NASH drug
- Seeking Alpha’s Quant Rating on Inventiva
- Historical earnings data for Inventiva